Lupin ( Lupin)

Primary tabs

Lupin's picture

Management

Contact Address

About Lupin

The company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish the land, the very soil it grows in. The Lupin flower is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes. The Lupin flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life.

Lupin press release, blog etc

Tue, 01/28/2025 - 17:51 Enables expanded access to the only EU-approved treatment for myotonia symptomsin adults with non-dystrophic myotonic disorders
Tue, 01/28/2025 - 17:51 Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.06%
Sun, 01/12/2025 - 01:52 Lupin Receives Tentative Approval from U.S. FDA for Ivacaftor Oral Granules
Sat, 11/23/2024 - 09:41 Lupin and NAPCON Hosts a Walkathon A Step Towards HealThy Lungs for COPD Awareness
Sat, 08/24/2024 - 13:09 Mr. Nilesh Gupta, Managing Director, Lupin said, Weare committed to providing affordable and high-quality treatment to our patients. The Health Canada approval for Armlupeg strengthens our ability to support Canadian patients with this mainstay treatment.
Mon, 08/05/2024 - 21:27 India, USA, Europe, Russia, August 05, 2024: Global Pharma major Lupin Limited (Lupin) today announced the successful completion of a global Phase 3 clinical study of LUBT010, its biosimilar candidate to Lucentis. The study has achieved its primary endpoi
Sun, 12/04/2022 - 20:51 Lupin Launches Rufinamide Tablets USP in the United States
Mon, 11/14/2022 - 07:54 Ben Ellis, General Manager Lupin Healthcare UK.
Tue, 11/08/2022 - 13:54 Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules
Thu, 10/20/2022 - 03:21 Lupin Launches Paliperidone Extended-Release Tablets in the United States
Wed, 10/19/2022 - 23:02 Mumbai, Naples, October 20, 2022 : Global pharmaceutical major Lupin Limited (Lupin) today announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuter
Tue, 09/13/2022 - 11:58 Lupin Receives Health Canada Approval for Rymti (biosimilar Etanercept)
Wed, 09/07/2022 - 04:19 Peter Dolinsky, Vice President Own Brands, Asia Pacific at DKSH
Thu, 08/25/2022 - 03:33 We are pleased to partner with Irom in Japan to bring this important biosimilar to the market. Biosimilars are a key growth driver for Lupin, and through products such as this, we are making significant progress in improving access and affordability of im
Tue, 07/19/2022 - 19:37 Expanding its Diagnostics Business footprint in East India
Wed, 06/15/2022 - 09:41 Patna, India | June 15, 2022: Global pharma major Lupin Limited (Lupin) announced today that Lupin Diagnostics has launched its first Regional Reference Laboratory in Patna, Bihar.
Fri, 05/06/2022 - 11:49 Memorandum & Articles of Association
Tue, 04/05/2022 - 14:29 Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region
more

InfoBox

HomePagewww.lupin.com
Twittertwitter.com/lupinlimited
LinkedInwww.linkedin.com/company/lupin
Wikipediaen.wikipedia.org/wiki/Lupin_Limited